Archive

Archive for the ‘Pharmaceutical Research and Manufacturers of America (PhRMA)’ Category

More than 100 New Medicines in Development to Treat Mental and Addictive Disorders

June 18, 2014 Comments off

More than 100 New Medicines in Development to Treat Mental and Addictive Disorders
Source: Pharmaceutical Research and Manufacturers of America (PhRMA)

America’s biopharmaceutical research companies currently are developing 119 novel new medicines to help improve the lives of the estimated 61.5 million Americans that are affected by mental health disorders, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

These medicines in development – all either in clinical trials or under review by the Food and Drug Administration (FDA) – include 36 for schizophrenia, 29 for depression, 20 for substance/addictive disorders, 15 for attention deficit/hyperactivity disorder and 15 for anxiety disorders.

Mental health conditions pose a heavy human and economic burden in the United States. According to the National Institute of Mental Health (NIMH), 1 in 4 American adults have been diagnosed with a mental health disorder – and serious mental illnesses cost the U.S. more than $317 billion annually in lost wages, health care expenditures and disability benefits.

About these ads

An Analysis of Exchange Plan Benefits for Certain Medicines

June 12, 2014 Comments off

An Analysis of Exchange Plan Benefits for Certain Medicines
Source: Pharmaceutical Research and Manufacturers of America (PhRMA)

A central goal of the Affordable Care Act (ACA) was to expand access to insurance so patients, particularly those with chronic disease, could access the treatments and medicines they need. Recognizing that coverage would have limited value without basic access and affordability, the ACA included a non-discrimination provision, an out-of-pocket spending cap, mandatory coverage of “essential health benefits,” and financial assistance for low-income enrollees.

Health insurers typically design “tiered” prescription drug benefits in which a patient’s cost varies depending on a drug’s tier placement (e.g., preferred, non-preferred, etc.). Tiering structures are therefore critical factors in affordability. Plans submit their formulary tiering structure, along with other aspects of the plan’s design, for review by the appropriate state or federal regulator to ensure they meet relevant requirements under the ACA.

Following a recent report that some exchange plans have placed all covered HIV/AIDS medicines on the highest tier, PhRMA engaged Avalere Health to determine the prevalence of such practices, which would appear to be at odds with the patient protections at the core of the ACA. Formularies that require high cost sharing for all medicines of a specific therapeutic type or “class” (e.g., insulins, statins, etc.) create access barriers for patients.

More Than 70 Medicines in Development for Asthma

March 9, 2012 Comments off

More Than 70 Medicines in Development for Asthma
Source: Pharmaceutical Research and Manufacturers of America (PhRMA)

America’s biopharmaceutical research companies are developing 74 medicines to treat or prevent asthma, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). All of the medicines are either in clinical trials or awaiting review by the Food and Drug Administration.

Asthma is a narrowing of the airways to the lungs caused by inflammation in the air passages, resulting from both genetic and environmental influences. Today, more than 24 million American adults and children suffer from asthma, with the prevalence increasing 12 percent in the last decade, according to the Centers for Disease Control and Prevention. Each day, 40,000 Americans miss school or work due to asthma, costing the U.S. economy an estimated $56 billion each year in direct and indirect costs.

+ Full Document (PDF)

Follow

Get every new post delivered to your Inbox.

Join 928 other followers